Antibody Ingredients TRIZ Cases

ROR1-binding monoclonal antibodies target ROR1-expressing cancer cells with high affinity for detection and treatment.

FcγR-mediated crosslinking can trigger cytokine release and other toxicities; L234A/L235A Fc mutations preserve CD40 activation while reducing this risk.

Blocking NgR1 activity or expression helps immune cells form stable synapses and improves cytolytic activity against cancer cells.

Targeted FRα binding directs camptothecin payloads into cancer cells, addressing off-target effects while supporting sustained intracellular release.

Humanized monoclonal antibodies target ILT3 while limiting cross-reactivity with ILT5, ILT7, ILT8, and ILT11.

Temperature-shifted de-glycation rates predict therapeutic protein glycation across storage conditions and guide glucose formulation for potency control.

Specific CD7-binding antibodies recruit CDC and ADCP to deplete relapsed or therapy-resistant T-ALL cells more effectively.

Specific ILT4 antibodies target myeloid cells while limiting LILR-family cross-reactivity to support T cell activation.

Linked Fab domains help regulate antigen interactions and resist protease cleavage, supporting agonist activity and therapeutic efficacy.

Protease cleavage activates the bispecific prodrug in the tumor microenvironment, enabling T-cell recruitment while limiting off-target toxicity.

Humanized 9b7 antibodies direct cytotoxic payloads to uPARAP-expressing cells, addressing weak ADC potency and healthy-cell toxicity.

Varied CDR3 sequences expand BCMA antibody options while conserved CDR1 and CDR2 regions support targeted binding for therapy.

Tunable anti-CD3 and anti-TAA binding affinity supports T-cell recruitment while limiting off-target toxicity and cytokine release.

Engineered anti-BTLA antibody CDRs target BTLA with high affinity to block BTLA-HVEM interaction and enhance immune signaling in cancer.

By increasing hepcidin expression, anti-TMPRSS6 antibodies reduce serum and liver iron while supporting erythropoiesis in iron overload disorders.

Lactobacillus paracasei postbiotics raise HLA class I on tumor cells, improving immune recognition and sensitizing them to ICI therapy.

Activated allogeneic CD4+ T-cells pre-condition cold metastatic colorectal tumors for checkpoint inhibition by increasing immune infiltration.

An anti-CLDN18.2 and anti-4-1BB bispecific antibody combines tumor recognition with immune activation for advanced solid tumors.

mCRPC therapies often provide limited benefit; PSMA-CD3 bispecific antibodies redirect T cells to tumors and can pair with PD-1 blockade.

Conventional ADCs face low cytotoxic potency and narrow therapeutic windows; fused ring conjugates strengthen targeted tumor-cell activity.

CCR8-targeted antibodies block CCL1 signaling and use ADCC to remove Treg cells that suppress anti-tumor immunity.

Fully canine antibodies target canine CD20 to address cross-species immunogenicity in potential B-cell lymphoma and leukemia treatment.

Fc modifications strengthen ADCP and ADNKA while extending antibody half-life for sustained malaria prophylaxis.

Existing 5T4 ADCs have struggled against tumors; pyridazine-pyrrolo coupling and tailored linkers support targeted delivery of cytotoxic drugs.

Targeted Fc substitutions favor activating FcγRIIa over inhibitory FcγRIIb while supporting pH-dependent FcRn binding for longer antibody blood half-life.

Camptothecin payloads, pH-sensitive linkers, and DAR 1–4 address limited GPC3 ADC efficacy while supporting targeted tumor-cell killing.

Monoclonal antibodies that inhibit complement C1s reduce autoantibody and alloantibody titers in complement-mediated immune disorders.

Site-specific drug attachment and dual CD47/PD-L1 targeting help this PEG-based ADC improve tumor selectivity while limiting off-target toxicity.

Combining mesothelin-targeted CAR cells with PD-L1 inhibitors improves tumor inhibition beyond either therapy alone.

Specific CDR sequences help anti-Lewis Y antibodies distinguish tumor glycans from normal tissue, reducing cross-reactivity and toxicity.

Anti-c-Met antibodies carry topoisomerase I inhibitors to c-Met-expressing tumor cells for more effective NSCLC treatment.

Conventional antibodies may not distinguish TNBC from other breast cancer subtypes; this VHH enables selective cell staining for recognition.

Compound A, a PDE4 inhibitor, addresses limited IPF treatment efficacy by reducing lung hydroxyproline and pro-fibrotic marker expression.

A macrocyclic compound remodels tumor vasculature and suppresses CAF activity, improving the cancer microenvironment.

A composite linker combining disulfide, peptide, and cleavable segments improves plasma stability and limits off-target toxicity.

Compare baseline and on-treatment IL-6, CRP, and CXCL10 levels to identify immunotherapy responders early and limit unnecessary therapy.

scFv fragments target CCR2 binding regions to inhibit CCL2 signaling, limit inflammatory monocyte migration, and support M1 polarization.

A low-affinity CD47 arm and high-affinity CD20 arm focus phagocytosis on tumor cells while limiting normal-cell binding and hematologic toxicity.

Measuring nuclear PD-L2 and its histone co-localization helps stratify likely therapy responders and non-responders for personalized treatment.

Selective ACTH binding avoids broader melanocortin interference while anti-ACTH antibodies reduce cortisol and aldosterone levels.

This case combines anti-PD-1 antibodies with CTLA-4 antibodies or anti-angiogenic TKIs to improve durable renal cancer responses.

Auristatin-conjugated CD25 antibodies target Tregs for depletion, supporting immune surveillance while minimizing adverse effects.

Targeted CDR substitutions humanize anti-CD47 antibodies while preserving affinity and specificity and reducing T-cell epitope content.

See how engineered anti-PD-L1 antibodies and camptothecin or MMAE ADCs improve binding, internalization, and tumor-cell killing.

Engineered CDR3 regions tune CTLA-4 binding proteins for selective immune modulation, therapeutic use, and Treg-directed ADCC.

Engineered Nectin-4 binding pairs with an exatecan payload to preserve anti-tumor activity while reducing skin toxicity.

Optimized IgG1 Fc domains improve heavy-chain pairing and reduce ADCC and CDC activity while activating T cells against tumor cells.

E345 and P329 Fc mutations enable CD27 antibodies to form hexamers without FcγR crosslinking, supporting potent agonism and variant binding.

Anti-CD1a antibodies target antigen-presenting cells to reduce inflammation without broad immune suppression.

See how anti-TIGIT antibodies block TIGIT–CD155 binding to activate T cells and NK cells, addressing limited cancer-treatment efficacy.